Lamotrigine

Evidence Level: L5

Predicted Indications: 2

Lamotrigine

Pharmacist Assessment Report

Lamotrigine: From Epilepsy to Trigeminal Nerve Neoplasm

One-Sentence Summary

Lamotrigine is an anticonvulsant originally used to treat epilepsy, including partial epilepsy and Lennox-Gastaut syndrome. The TxGNN model’s (deep learning) top-ranked prediction is trigeminal nerve neoplasm, but this score comes from the TxGNN model and may reflect similarities the model learned between related diseases, not biological evidence, with 0 clinical trials and only 2 publications, neither of which concerns neoplasm treatment. The closely related prediction, trigeminal neuralgia, has far stronger support (2 completed clinical trials and 18 publications), so it is the more credible repurposing direction and is discussed alongside the top-ranked item below.

Quick Overview

Item	Content
Original Indication	Epilepsy (partial epilepsy, Lennox-Gastaut syndrome)
Predicted New Indication	Trigeminal nerve neoplasm (rank 1); trigeminal neuralgia (rank 2) is the better-supported alternative
TxGNN Prediction Score	0.9997 (trigeminal nerve neoplasm); 0.9989 (trigeminal neuralgia)
Evidence Level	L5 (trigeminal nerve neoplasm); L2 (trigeminal neuralgia)
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold (trigeminal nerve neoplasm); Proceed with Guardrails (trigeminal neuralgia)

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, lamotrigine blocks voltage-gated sodium channels and reduces glutamate release, which underlies its effect in epilepsy.

Trigeminal nerve neoplasm: The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as trigeminal neuralgia, not biological evidence of a true anti-tumour effect. There is no evidence that lamotrigine acts on tumour biology. The two papers retrieved concern trigeminal neuralgia (a general treatment review and a Gamma Knife case report for a cavernous malformation), not neoplasm treatment.

Trigeminal neuralgia: The rationale here is much stronger. Trigeminal neuralgia involves focal demyelination and ectopic, hyperexcitable firing of trigeminal afferents. Sodium channel blockade dampens this firing, the same mechanism as carbamazepine and oxcarbazepine, the first-line agents. The European Academy of Neurology guideline (2019) lists lamotrigine as an add-on or second-line option. A practical constraint is the slow dose titration needed to limit rash risk (including Stevens-Johnson syndrome), which is awkward in a condition with severe acute pain.

Clinical Trial Evidence

Trigeminal nerve neoplasm: Currently no related clinical trials registered.

Trigeminal neuralgia:

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00913107	Phase 2/3	Completed	21	Lamotrigine compared with carbamazepine for efficacy and safety in trigeminal neuralgia; small sample limits conclusions
NCT00203229	NA	Completed	20	Double-blind, placebo-controlled add-on study of lamotrigine in trigeminal neuralgia; underpowered

No ANZCTR identifiers were identified in the data compiled for this report.

Literature Evidence

Trigeminal nerve neoplasm:

PMID	Year	Type	Journal	Key Findings
17997704	2007	Review	Expert Rev Neurother	Overview of medical and surgical treatments for trigeminal neuralgia; not about neoplasm
30650431	2018	Case report	Stereotact Funct Neurosurg	Gamma Knife radiosurgery for trigeminal neuralgia caused by a cavernous malformation

Trigeminal neuralgia (selected):

PMID	Year	Type	Journal	Key Findings
30860637	2019	Guideline	Eur J Neurol	European Academy of Neurology guideline on trigeminal neuralgia management
37892981	2023	Systematic Review	Biomedicines	Umbrella review of drugs used for trigeminal neuralgia, their efficacy and side effects
38870050	2024	Review	Expert Rev Neurother	Pharmacotherapy update: carbamazepine and oxcarbazepine are effective but limited by adverse effects; newer agents are possible adjuncts
34108244	2021	Review	Pract Neurol	Practical guide to diagnosis and medical and surgical treatment
31908187	2020	Review	Mol Pain	Pathophysiology and pharmacological treatments
30178160	2018	Review	Drugs	Current and innovative pharmacological options for typical and atypical trigeminal neuralgia
38246671	2024	Review	No Shinkei Geka	Notes lamotrigine is used off-label in Japan as an alternative to carbamazepine
11903537	2001	Review	Headache	Antiepileptic drugs in cluster headache and trigeminal neuralgia

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13842M	Lamictal	Tablet 25 mg	Not available in the data compiled for this report

Safety Considerations

Key Warnings and Contraindications: Label-based data were not available. Please refer to the TGA-approved Product Information (PI). Rash, including Stevens-Johnson syndrome, is a recognised risk with lamotrigine and drives the slow titration schedule.
Knowledge-graph contraindication signals (not label text): liver disease, gallbladder disease, and haematological conditions (thrombocytopenia, neutropenia, agranulocytosis, anaemia, pancytopenia, aplastic anaemia), as well as non-infectious meningitis, anxiety disorder, neurotic disorder and dysthymic disorder. These should be checked against the PI.
Drug Interactions: 100 interactions were identified in total. Moderate-level interactions include morphine (including liposomal), opium, dronabinol, nabilone, metoclopramide and orlistat. Metformin is listed as minor. Several others (e.g. omeprazole, pantoprazole, doxycycline, glimepiride) have an unknown severity level.

Other Predicted Indications (Brief)

Predicted Indication	Evidence Level	Key Point	Recommendation
Startle epilepsy	L3	Two small case series report benefit (PMIDs 10512780, 21896426); no registered trials	Research Question
Restless legs syndrome	L3	One 2005 pilot trial (15680305) and case reports; no registered trials; not an established therapy	Research Question
Audiogenic seizures	L4	Animal-model evidence only	Research Question
Orgasm-induced, eating, thinking, micturition-induced and reading seizures	L4-L5	No indication-specific lamotrigine data; likely inferred from the parent epilepsy classification	Hold

Conclusion and Next Steps

Decision: Hold (trigeminal nerve neoplasm, the top-ranked prediction); Proceed with Guardrails (trigeminal neuralgia)

Rationale:

The top-ranked prediction, trigeminal nerve neoplasm, has no supporting trials and no evidence of anti-tumour activity; it is most likely a TxGNN model (deep learning) artefact. Trigeminal neuralgia is a plausible, guideline-recognised second-line use, supported by two small completed trials, but no adequately powered Phase 3 RCT is confirmed.

To proceed, the following is needed:

Confirmation of the intended indication (neoplasm versus neuralgia) before any further work
An adequately powered, controlled trial of lamotrigine in trigeminal neuralgia
Detailed mechanism of action data
The TGA-approved indication text and PI warnings and contraindications, including a rash and titration plan suited to acute pain
Review of the haematological and hepatic signals and the drug interaction profile for the target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.